Novartis, Novo heart drug setbacks challenge treatment hopes
Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed to reduce cardiovascular events despite targeting Lp(a) and inflammation. Novartis' drug, tested on 8,300 patients, showed no benefit in preventing heart attacks or strokes. Novo Nordisk's trial on 6,300 patients also showed no reduction in major cardiovascular events. Both companies presented findings at the American Heart Association meeting.
How this was made
The 30-second read
Why it matters
The failures underscore the difficulty of translating Lp(a) reduction into clinical benefit and may redirect R&D spending.
Market read
Biotech investors will reassess cardiovascular pipeline valuations; short‑term volatility expected for the two stocks.
What to watch
Potential for future combination therapies or next‑generation antisense/RNA platforms could mitigate short‑term disappointment.
Background
Both trials were presented at the American Heart Association meeting, marking the first public disclosure of the results.
Ticker impact
Novartis' pelacarsen trial failed to meet primary endpoint, showing no cardiovascular benefit despite Lp(a) reduction.
likely downward pressure as investors reassess cardiovascular franchise value
First disclosure of a major Phase 3 failure for a high‑profile antisense drug; market typically reacts sharply to such setbacks.
Novo Nordisk's anti‑inflammatory drug ziltivekimab failed to reduce major cardiovascular events in a large trial.
potential short‑term pressure as investors weigh reduced growth outlook
First report of a late‑stage trial miss for a key pipeline candidate; investors typically penalize biotech stocks on such news.
Market effects
Highlights challenges in Lp(a) targeting strategies, may shift investor focus to RNA‑based approaches.
US biotech sector may see modest pullback; European peers with similar programs could be affected.
Limited to cardiovascular drug developers; broader market impact minimal.
Counterpoint
Some investors may view the setbacks as a buying opportunity if they believe the underlying science still holds long‑term value.
Key entities
- CompanyNovartis
Swiss pharma giant developing pelacarsen.
- CompanyNovo Nordisk
Danish drugmaker testing ziltivekimab.
